Claritev Corporation (CTEV)
| Market Cap | 667.56M -43.6% |
| Revenue (ttm) | 994.67M +6.3% |
| Net Income | -283.11M |
| EPS | -16.99 |
| Shares Out | 16.95M |
| PE Ratio | n/a |
| Forward PE | 5.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 132,980 |
| Open | 38.06 |
| Previous Close | 38.78 |
| Day's Range | 37.85 - 39.65 |
| 52-Week Range | 11.50 - 74.07 |
| Beta | 0.79 |
| Analysts | Buy |
| Price Target | 45.83 (+16.35%) |
| Earnings Date | Aug 7, 2026 |
About CTEV
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and revenue integrity solutions comprising clinical neg... [Read more]
Financial Performance
In 2025, Claritev's revenue was $965.41 million, an increase of 3.74% compared to the previous year's $930.62 million. Losses were -$284.28 million, -82.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CTEV stock is "Buy." The 12-month stock price target is $45.83, which is an increase of 16.35% from the latest price.
News
Claritev Corporation Announces Participation in Upcoming Events
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that members of its management team ...
Claritev price target raised to $40 from $28 at Barclays
Barclays analyst Glen Santangelo raised the firm’s price target on Claritev (CTEV) to $40 from $28 and keeps an Overweight rating on the shares.
Marpai expand relationship with Claritev
Claritev (CTEV) Corporation announced that Marpai has expanded its relationship with Claritev to bring comprehensive pre- and post-payment integrity capabilities to the health plans and claims it admi...
Marpai Expands Relationship with Claritev to Help Reduce Healthcare Costs for Employer Clients
MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #ClaimsManagement--Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that Marpai, Inc. (OTCQX: MRAI) has ex...
Claritev price target raised to $30 from $22 at Wells Fargo
Wells Fargo raised the firm’s price target on Claritev (CTEV) to $30 from $22 and keeps an Equal Weight rating on the shares. Claritev’s Q2 beat, raised FY26 outlook, and…
Claritev Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company is executing a multi-year transformation focused on digital innovation, operational excellence, and market expansion, with strong financial momentum and a robust sales pipeline. Litigation risks are being managed, and regulatory changes like the No Surprises Act are driving product growth.
Claritev price target raised to $43 from $37 at Canaccord
Canaccord raised the firm’s price target on Claritev (CTEV) to $43 from $37 and keeps a Buy rating on the shares. The firm updated its model following beat and raise…
Claritev price target raised to $45 from $40 at Citi
Citi analyst Daniel Grosslight raised the firm’s price target on Claritev (CTEV) to $45 from $40 and keeps a Buy rating on the shares.
Claritev Earnings Call Transcript: Q2 2026
Q2 results exceeded expectations with revenue up 6.6% year-over-year and record cash flow. Strong bookings and pipeline growth support raised full-year guidance, while digital transformation and AI initiatives drive efficiency and client value.
Claritev Slides: Q2 2026
Claritev has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 7, 2026.
Claritev Earnings release: Q2 2026
Claritev released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Claritev Quarterly report: Q2 2026
Claritev has published its Q2 2026 quarterly earnings report on August 7, 2026.
Claritev raises FY26 revenue view to $1B-$1.02B from $985M-$1B
Consensus $993.39M. Raises FY26 adjusted EBITDA view to $620M-$620M from $605M-$615M. Backs FY26 capital expenditures view $160M-$170M. Dalton added, “This success is most clearly reflected in our boo...
Claritev reports Q2 EPS ($3.49) vs. ($3.81) last year
Reports Q2 revenue $257.48M, consensus $244.81M. “Claritev (CTEV) once again demonstrated the strength of our vision and strategy in the second quarter of 2026, delivering financial results above expe...
Claritev Corporation Reports Second Quarter 2026 Results
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fai...
Claritev Corporation Announces Participation in Canaccord Genuity 46th Annual Growth Conference
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data, and insights company focused on making healthcare more affordable, transparent and fa...
Claritev: Handled more federal IDR claims than any other non-payor participant
Claritev (CTEV) announced that, according to newly released 2025 data from the Centers for Medicare & Medicaid Services, the Company handled more federal Independent Dispute Resolution claims than any...
Claritev Demonstrates Market Leadership as Federal No Surprises Act Disputes Reach Record Levels
MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #HealthcareAffordability--Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more affordable, tr...
Claritev™ and SAVVI Financial® Collaborate to Deliver the Next Generation of Healthcare Benefit Decision Support
New solution combines claims-informed intelligence with AI-powered financial guidance to help employees make smarter benefits decisions MCLEAN, Va. and WALTHAM, Mass.
Claritev Adopts CodeTogether's AITrax to Bring Greater Measurement and Accountability to AI-Assisted Development
Claritev will use CodeTogether's AITrax to help measure adoption, cost, quality, and value across its enterprise AI-assisted software development initiatives. MCLEAN, Va.
Claritev price target raised to $37 from $32 at Canaccord
Canaccord raised the firm’s price target on Claritev (CTEV) to $37 from $32 and keeps a Buy rating on the shares. The firm updated its model heading into the earnings…
Sun Life U.S. and Claritev work to boost efficiency of supplemental health benefits
WELLESLEY, Mass. and MCLEAN, Va., July 16, 2026 /PRNewswire/ -- Sun Life U.S., a leading provider of employee and government benefits, and Claritev, a healthcare technology, data and insights company,...
Claritev Corporation Announces Second Quarter 2026 Earnings Conference Call
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transpar...
Justice Department expands antitrust probe into Claritev, Bloomberg says
The Justice Department is expanding an antitrust investigation into Claritev (CTEV) over allegations the company helped insurers, including UnitedHealth (UNH), CVS Health’s (CVS) Aetna and Cigna (CI),...
DOJ expands Claritev antitrust investigation, Bloomberg reports
13:00 EDT DOJ expands Claritev (CTEV) antitrust investigation, Bloomberg reports